This company listing is no longer active
La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !
MorphoSys Crescita futura
Future criteri di controllo 2/6
MorphoSys is forecast to grow earnings and revenue by 59.1% and 25% per annum respectively. EPS is expected to grow by 78.2% per annum. Return on equity is forecast to be 7.7% in 3 years.
Informazioni chiave
59.1%
Tasso di crescita degli utili
78.2%
Tasso di crescita dell'EPS
| Biotechs crescita degli utili | 35.4% |
| Tasso di crescita dei ricavi | 25.0% |
| Rendimento futuro del capitale proprio | 7.7% |
| Copertura analitica | Good |
| Ultimo aggiornamento | 05 Aug 2024 |
Aggiornamenti recenti sulla crescita futura
Recent updates
Previsioni di crescita degli utili e dei ricavi
| Data | Ricavi | Guadagni | Flusso di cassa libero | Liquidità dell'operazione | Avg. Numero di analisti |
|---|---|---|---|---|---|
| 12/31/2026 | 425 | -78 | -120 | -50 | 5 |
| 12/31/2025 | 322 | -140 | -236 | -201 | 8 |
| 12/31/2024 | 180 | -249 | -296 | -253 | 3 |
| 3/31/2024 | 241 | -469 | -286 | -284 | N/A |
| 12/31/2023 | 238 | -190 | -299 | -296 | N/A |
| 9/30/2023 | 223 | 104 | -363 | -355 | N/A |
| 6/30/2023 | 255 | 100 | -349 | -338 | N/A |
| 3/31/2023 | 261 | -61 | -321 | -306 | N/A |
| 12/31/2022 | 278 | -151 | -382 | -367 | N/A |
| 9/30/2022 | 250 | -861 | -436 | -417 | N/A |
| 6/30/2022 | 195 | -851 | -606 | -588 | N/A |
| 3/31/2022 | 174 | -596 | -610 | -583 | N/A |
| 12/31/2021 | 180 | -514 | -508 | -481 | N/A |
| 9/30/2021 | 163 | -150 | -423 | -393 | N/A |
| 6/30/2021 | 143 | -103 | -295 | -246 | N/A |
| 3/31/2021 | 124 | -177 | -255 | -217 | N/A |
| 12/31/2020 | 328 | 98 | -14 | 35 | N/A |
| 9/30/2020 | 303 | 64 | 26 | 63 | N/A |
| 6/30/2020 | 293 | 105 | 98 | 113 | N/A |
| 3/31/2020 | 309 | 153 | 137 | 152 | N/A |
| 12/31/2019 | 72 | -103 | -85 | -81 | N/A |
| 9/30/2019 | 71 | -96 | -68 | -64 | N/A |
| 6/30/2019 | 114 | -42 | -42 | -39 | N/A |
| 3/31/2019 | 87 | -59 | -33 | -31 | N/A |
| 12/31/2018 | 76 | -56 | -35 | -33 | N/A |
| 9/30/2018 | 94 | -27 | -16 | -14 | N/A |
| 6/30/2018 | 54 | -82 | -61 | -48 | N/A |
| 3/31/2018 | 58 | -74 | -68 | -55 | N/A |
| 12/31/2017 | 67 | -70 | N/A | -38 | N/A |
| 9/30/2017 | 52 | -84 | N/A | -52 | N/A |
| 6/30/2017 | 49 | -73 | N/A | -59 | N/A |
| 3/31/2017 | 49 | -68 | N/A | -47 | N/A |
| 12/31/2016 | 50 | -60 | N/A | -47 | N/A |
| 9/30/2016 | 49 | -45 | N/A | -48 | N/A |
| 6/30/2016 | 48 | -40 | N/A | -41 | N/A |
| 3/31/2016 | 48 | -33 | N/A | -35 | N/A |
| 12/31/2015 | 106 | 15 | N/A | -24 | N/A |
| 9/30/2015 | 111 | 27 | N/A | -15 | N/A |
| 6/30/2015 | 116 | 33 | N/A | -3 | N/A |
| 3/31/2015 | 119 | 37 | N/A | -4 | N/A |
| 12/31/2014 | 64 | -3 | N/A | -14 | N/A |
| 9/30/2014 | 61 | -6 | N/A | -15 | N/A |
| 6/30/2014 | 60 | -5 | N/A | 79 | N/A |
| 3/31/2014 | 77 | 7 | N/A | 76 | N/A |
| 12/31/2013 | 78 | 7 | N/A | 89 | N/A |
| 9/30/2013 | 80 | 14 | N/A | 100 | N/A |
Previsioni di crescita futura degli analisti
Guadagni vs tasso di risparmio: MOR is forecast to remain unprofitable over the next 3 years.
Guadagni vs Mercato: MOR is forecast to remain unprofitable over the next 3 years.
Guadagni ad alta crescita: MOR is forecast to remain unprofitable over the next 3 years.
Ricavi vs Mercato: MOR's revenue (25% per year) is forecast to grow faster than the Swiss market (4.8% per year).
Ricavi ad alta crescita: MOR's revenue (25% per year) is forecast to grow faster than 20% per year.
Previsioni di crescita dell'utile per azione
Rendimento futuro del capitale proprio
ROE futuro: MOR's Return on Equity is forecast to be low in 3 years time (7.7%).